They may also be appropriate for people who want to avoid injections or have difficulty with injectable medications
For healthcare professionals and licensed practitioners operating within appropriate regulatory frameworks, access to advanced therapeutic tools continues to expand as research progresses
J Pediatr Endocrinol Metab (2016) 1;29(8):91522
In Q3 2025, it reported $599.0 million in revenue, 2.471 million subscribers, and $80 in monthly online revenue per average subscriber
Feeling cold while taking GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound)the latter being a dual GIP/GLP-1 receptor agonistis something many patients report anecdotally, though it is not listed as an official adverse effect in FDA-approved labeling for these medications
This patient approach matters more than most people realize